Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 4OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 6Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Urinary Bladder Neoplasms 2Nasopharyngeal Carcinoma 2Hodgkin Disease 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Renal Insufficiency 1Neoplastic Cells, Circulating 1Locally Advanced Cervical Cancer 1Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement 1Carcinoma, Transitional Cell 1

Interventions

veliparib 1avelumab 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Testicular Neoplasms × Gemcitabine × Clear all
NCT02860819 2021-03-03

Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer

National Cancer Institute, Slovakia

Phase 2 Completed
15 enrolled
Genitourinary

Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡